For instance, a phase II trial (TRICK-MCC) is evaluating triplet therapy with PD-1, LAG-3, and TIM-3 antibodies in patients with advanced MCC that progressed after PD-1 inhibitor treatment. Here, LAG3 is linked to Merkel cell skin cancer.